AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
03 nov. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
02 nov. 2023 07h00 HE
|
AC Immune SA
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
05 sept. 2023 07h00 HE
|
AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
04 août 2023 07h00 HE
|
AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...
AC Immune SA Appoints New Chief Medical Officer
26 juil. 2023 07h00 HE
|
AC Immune SA
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
03 juil. 2023 07h00 HE
|
AC Immune SA
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
30 mai 2023 09h00 HE
|
Silo Pharma, Inc.
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Alzheimer’s Disease Diagnostic Market Size Worth USD 7100 Million by 2030 at 8.90% CAGR – Report by Market Research Future (MRFR)
24 mai 2023 14h00 HE
|
Market Research Future
New York, May 24, 2023 (GLOBE NEWSWIRE) -- Alzheimer’s Disease Diagnostic Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Alzheimer’s Disease...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
25 avr. 2023 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
Silo Pharma to Present at Psychedelic Drug Development Conference
24 avr. 2023 08h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...